Medexus Pharmaceuticals (MDP) Competitors

Canopy Growth (TSE:WEED) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Do insiders and institutionals hold more shares of WEED or MDP?

9.4% of Canopy Growth shares are owned by institutional investors. Comparatively, 8.3% of Medexus Pharmaceuticals shares are owned by institutional investors. 0.2% of Canopy Growth shares are owned by insiders. Comparatively, 9.1% of Medexus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Is WEED or MDP more profitable?

Medexus Pharmaceuticals has a net margin of 3.25% compared to Canopy Growth's net margin of -201.27%. Medexus Pharmaceuticals' return on equity of 11.07% beat Canopy Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-201.27%	-108.18%	-3.83%
Medexus Pharmaceuticals	3.25%	11.07%	4.89%

Do analysts rate WEED or MDP?

Canopy Growth presently has a consensus target price of C$2.20, suggesting a potential upside of 25.71%. Medexus Pharmaceuticals has a consensus target price of C$5.49, suggesting a potential upside of 81.11%. Given Medexus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Medexus Pharmaceuticals is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	3 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medexus Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	4 Strong Buy rating(s)	3.29

Which has stronger valuation and earnings, WEED or MDP?

Medexus Pharmaceuticals has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	C$519.68M	0.54	-C$1.05B	-C$6.85	-0.26
Medexus Pharmaceuticals	C$100.25M	0.68	C$3.26M	C$0.21	14.49

Which has more risk & volatility, WEED or MDP?

Canopy Growth has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Comparatively, Medexus Pharmaceuticals has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500.

Does the media prefer WEED or MDP?

In the previous week, Medexus Pharmaceuticals had 5 more articles in the media than Canopy Growth. MarketBeat recorded 7 mentions for Medexus Pharmaceuticals and 2 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.21 beat Medexus Pharmaceuticals' score of -0.19 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Canopy Growth	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medexus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Medexus Pharmaceuticals beats Canopy Growth on 14 of the 17 factors compared between the two stocks.